castration-resistant prostate cancer research hub
4 indexed studies · 2 currently recruiting
- recruitingTherapeutic exploratory (Phase II)
Phase 2 INSPIRE trial: Ipilimumab with Nivolumab in molecular-selected patients with castration-resistant prostate cancer
This study is testing two new medicines, YERVOY and OPDIVO, for men with prostate cancer that has spread and is no longer responding to standard hormone therapy. We want to see how well they control the cancer and if they cause any side effects.
Netherlands - not yet recruitingPHASE2
Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer
This study is testing a new drug called evofosfamide alongside a standard prostate cancer treatment (ARSI) for men whose prostate cancer has spread and is no longer responding to initial hormone therapy. It aims to see if this new combination works better.
Canada - active not recruitingPHASE1
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This study is testing two anti-cancer drugs, cabozantinib and atezolizumab, alone and together, for various advanced cancers. It aims to find a safe combination dose and see how well it works and any side effects.
United States · Australia · Belgium - active not recruitingPHASE1, PHASE2
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
This study is testing a new drug, HMBD-001, for advanced cancers where a protein called HER3 is active. We want to find the best dose, understand side effects, and see if it helps stop cancer growth, sometimes with another drug called enzalutamide.
United Kingdom